As an example, the case of ERCC1 in lung cancer, where a high ERCC1 expression is associated with improved survival but a worse outcome after cisplatin-based adjuvant chemotherapy.25 Focusing on the two molecular alterations that stratified according to prognosis, DDR2 mutations were detected in 5% of our cohort, similar to what was previously described.26 Of interest, while to date, no correlation between DDR2 mutations and survival has been reported,27 we observed a significant trend for improved survival in DDR2 mutant patients, all belonging to the GP group. The gene discussed is ERCC1; the disease is lung carcinoma.